The Salt Study for Heart Failure
This study, called "The Salt Study for Heart Failure," is looking into whether a low-sodium (salt) diet is truly necessary for people who have experienced heart failure. Researchers want to see if different salt intakes affect how often patients need to be readmitted to the hospital within 30 days of discharge. You might be able to join if you are over 18 and have been hospitalized for heart failure within the last 24 hours. However, you cannot participate if you have very high blood pressure, end-stage kidney disease (on dialysis), or cardiogenic shock (a severe type of heart failure). The study is comparing a "Normal Salt Diet" (3-4 grams of salt per day) with a "Cardiac Diet" (2 grams of salt per day), which is the standard recommendation. The study aims to understand if a normal salt diet is safe and effective for patients with acute heart failure. The current status of the study is unclear, and it plans to enroll 500 participants.
- Study design
- This interventional study plans to enroll 500 participants. It compares two different diets: a Normal Salt Diet and a Cardiac Diet.
- What's involved
- You would follow either a Normal Salt Diet or a Cardiac Diet while in the hospital. After discharge, you would follow routine clinical care recommendations.
- Compensation
- Not stated in the trial record.
- Follow-up
- Researchers will track your length of hospital stay, 30-day readmission after discharge, and NT-proBNP levels (a marker for heart failure) from admission up to 30 days after discharge.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
The Salt Study for Heart Failure
At a glance
Conditions
NCT07560592
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Robert Wood Johnson Barnabas Hospital - New Brunswick
New Brunswick, New Jerseystudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Maya Guglin, MD · PRINCIPAL_INVESTIGATOR · Rutgers University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Length of hospital stayHospital admission to time of discharge assessed up to 1 year
number of days the patient remains hospitalized
- 30-day readmission30 days after discharge from hospital after index event
readmission to hospital within 30 days of discharge from the index event
- NT-proBNP on dischargetime of hospital admission to 30 days after discharge
Measurement of blood levels of NT-ProBNP a biomarker for diagnosing and assessing the severity of heart failure.
- Loop diuretic requirement during index admissiontime of hospital admission to 30 days after discharge
Furosemide, torsemide, and bumetanide are specific loop diuretics used in the treatment of fluid overload / retention conditions like congestive heart failure.